STOCK TITAN

QuidelOrtho Corporation (QDEL) Financials

QDEL NASDAQ
Trailing 12 months to September 27, 2026
Revenue $2.6B -4.5% YoY
Net Income -$369.2M n/m YoY
EPS (Diluted) -$5.39 n/m YoY
Free Cash Flow -$117.9M n/m YoY
Market Cap $570.9M as of Nov 20, 2026
Price / Sales 0.2x on $2.6B revenue, trailing 12 months to September 27, 2026
Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to September 27, 2026
Price / Book 0.3x on $1.8B equity, Q3 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Nov 20, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q3 FY2026, ended Sep 27, 2026 Reported Currency USD FYE December

Newest figures come from the 10-Q for Q3 FY2026, filed Nov 4, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the QDEL SEC filings page.

QuidelOrtho Corporation (QDEL) reported $2.6B in revenue over the twelve months to Sep 27, 2026, down 4.5% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 6 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI QDEL FY2025

QuidelOrtho’s recently steadied sales now support a business with weaker cost absorption and more leverage against equity.

The balance-sheet shift is more important than the small sales change: liabilities were nearly unchanged, down 1.8%, while equity fell sharply by 61.1% from FY2022 to FY2025. Debt-to-equity rose from 0.5x to 1.3x, so financing is now heavier relative to owners’ capital.

Revenue is down 16.4% from FY2022 to FY2025, while selling and administrative expense rose 20.2%; the overhead base therefore did not contract with the business. Operating margin moved from 25.8% to -33.7%, showing that lower volume and persistent overhead translated into operating losses rather than merely thinner margins.

FY2025 operations generated $105M, but capital spending reached $188M. That mismatch left free cash flow negative at -$83M, so reported operating cash generation did not fund the reinvestment burden.

[ NOT FINANCIAL ADVICE ]

Financial Health Signals

Profitability Growth Leverage Liquidity CashFlow Returns 21 / 100
Financial Health Score 21/100

Scored against operating companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of QuidelOrtho Corporation's business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Profitability
7

Profitability ranks operating companies on their operating margin with gains on asset sales taken out, averaged over the last three fiscal years with the newest counting most, and in smaller part on how steady that margin has been. QuidelOrtho Corporation scores 7/100 on it among other operating companies.

Growth
18

Growth ranks operating companies on the yearly rate at which revenue compounded across the last three fiscal years (the last two where the earliest reports no revenue), counted in the currency each company reports in so that a move in the exchange rate is not read as growth. QuidelOrtho Corporation scores 18/100 on it among other operating companies.

Leverage
28

QuidelOrtho Corporation carried $1.29 of long-term debt for every $1 of shareholders' equity at the end of fiscal year 2025, a debt-to-equity ratio of 1.29. With no positive EBITDA in fiscal year 2025, QuidelOrtho Corporation is ranked on that ratio rather than on net debt against EBITDA, a lower ratio being the safer one, and scores 28/100 among other operating companies measured the same way.

Liquidity
42

QuidelOrtho Corporation held $1.50 of current assets for every $1 of current liabilities at the end of fiscal year 2025, a current ratio of 1.50. Liquidity ranks operating companies on that ratio, and QuidelOrtho Corporation scores 42/100 among other operating companies.

Cash Flow
22

Cash Flow ranks operating companies on their free cash flow margin, which is operating cash flow less capital spending as a share of revenue, averaged over the last three fiscal years with the newest weighted most. QuidelOrtho Corporation scores 22/100 on it among other operating companies.

Returns
8

Returns ranks operating companies on their return on capital employed, which is operating income against total assets less current liabilities, averaged over three fiscal years with the newest weighted most, and in smaller part on how steady that return has been. QuidelOrtho Corporation scores 8/100 on it among other operating companies.

Altman Z-Score Distress
-0.11

QuidelOrtho Corporation scores -0.11, below the 1.81 distress threshold. The score is pulled down most by an operating loss of $919.2M against total assets of $5.8B. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Neutral
6/9

QuidelOrtho Corporation passes 6 of 9 financial strength tests. 3 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass, both operating efficiency signals pass.

Earnings Quality Mixed
N/A

QuidelOrtho Corporation reported a net loss of $1.1B while generating $105.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal.

Interest Coverage At Risk
N/A

QuidelOrtho Corporation reported an operating loss of $919.2M against $177.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue
$618.9M
YoY-11.6%
QoQ-1.9%

QuidelOrtho Corporation generated $618.9M in revenue in Q3 2026. This represents a decrease of 11.6% from the same quarter a year earlier. Against the prior quarter it is down 1.9%.

EBITDA
$112.1M
YoYn/m
QoQ+18.1%

QuidelOrtho Corporation's EBITDA was $112.1M in Q3 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. Against the prior quarter it is up 18.1%.

Net Income
-$53.8M
YoYn/m
QoQn/m

QuidelOrtho Corporation reported a net loss of $53.8M in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)
-$0.78
YoYn/m
QoQn/m

QuidelOrtho Corporation earned -$0.78 per diluted share (EPS) in Q3 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow
-$1.4M
YoYn/m
QoQn/m
5Y CAGRn/m

QuidelOrtho Corporation recorded an outflow of $1.4M in free cash flow in Q3 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt
$166.4M
YoY+69.6%
QoQ+34.8%
5Y CAGR-22.1%

QuidelOrtho Corporation held $166.4M in cash against $2.5B in long-term debt as of Q3 2026.

Shares Outstanding
69M
YoY+1.0%
QoQ+0.1%

QuidelOrtho Corporation had 69M shares outstanding in Q3 2026. This represents an increase of 1.0% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q3 2026.

Margins & Returns

Gross Margin
46.8%
YoY-1.2pp
QoQ+3.5pp

QuidelOrtho Corporation's gross margin was 46.8% in Q3 2026, indicating the percentage of revenue retained after direct costs. This is down 1.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 3.5 percentage points.

Operating Margin
-1.2%
QoQ+2.3pp

QuidelOrtho Corporation's operating margin was -1.2% in Q3 2026, reflecting core business profitability. Against the prior quarter it is up 2.3 percentage points. No change is given against Q3 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin
-8.7%
QoQ+6.0pp

QuidelOrtho Corporation's net profit margin was -8.7% in Q3 2026, showing the share of revenue converted to profit. Against the prior quarter it is up 6.0 percentage points. No change is given against Q3 2025: its reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity
-3.0%
YoY+33.0pp
QoQ+2.2pp
5Y change-16.2pp

QuidelOrtho Corporation's quarterly ROE was -3.0% in Q3 2026: one quarter's net income over shareholder equity, not annualized. This is up 33.0 percentage points from the same quarter a year earlier. Against the prior quarter it is up 2.2 percentage points.

Capital Allocation

R&D Spending
$42.5M
YoY+2.4%
QoQ-12.7%

QuidelOrtho Corporation invested $42.5M in research and development in Q3 2026. This represents an increase of 2.4% from the same quarter a year earlier. Against the prior quarter it is down 12.7%.

Capital Expenditures
$21.0M
YoY-58.0%
QoQ-17.6%
5Y CAGR-27.8%

QuidelOrtho Corporation invested $21.0M in capex in Q3 2026, funding long-term assets and infrastructure. This represents a decrease of 58.0% from the same quarter a year earlier. Against the prior quarter it is down 17.6%.

Share Buybacks

Not reported for Q3 2026.

QDEL Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QDEL quarterly income statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Revenue$618.9M-11.6%$630.9M+2.8%$619.8M-10.5%$723.6M+2.2%$699.9M-3.7%$613.9M-3.6%$692.8M-2.6%$707.8M-4.7%
Cost of Revenue$329.3M-9.6%$358.0M+5.6%$356.0M+1.9%$403.2M+5.6%$364.3M-2.8%$339.0M-6.1%$349.5M-7.8%$381.7M+6.0%
Gross Profit$289.6M-13.7%$272.9M-0.7%$263.8M-23.2%$320.4M-1.7%$335.6M-4.7%$274.9M-0.4%$343.3M+3.4%$326.1M-14.8%
R&D Expenses$42.5M+2.4%$48.7M+6.6%$44.9M-15.6%$45.8M-3.2%$41.5M-25.8%$45.7M-18.8%$53.2M-10.1%$47.3M-19.6%
SG&A Expenses$182.7M-2.2%$189.7M+6.6%$199.3M+6.6%$194.4M+3.7%$186.9M+0.3%$178.0M-5.4%$187.0M-8.6%$187.5M-0.1%
Operating Income-$7.5Mn/m-$21.8Mn/m-$31.8M-197.5%-$66.3Mn/m-$704.8M-4798.7%-$180.7Mn/m$32.6Mn/m-$100.4M-350.4%
EBITDA$112.1Mn/m$94.9Mn/m$81.1M-41.9%$46.2M+419.1%-$592.7M-562.7%-$70.4Mn/m$139.7Mn/m$8.9M-94.3%
Interest Expense$55.4M+20.2%$54.7M+35.1%$51.1M+27.8%$51.0M+25.6%$46.1M+7.5%$40.5M-1.2%$40.0M+2.6%$40.6M
Income Tax-$9.1Mn/m$11.7M-54.7%$12.3M+215.4%$18.3M-51.2%-$23.9Mn/m$25.8Mn/m$3.9Mn/m$37.5Mn/m
Net Income-$53.8Mn/m-$92.9Mn/m-$91.8Mn/m-$130.7Mn/m-$733.0Mn/m-$255.4Mn/m-$12.7Mn/m-$178.4M-2648.6%
EPS (Basic)-$0.78n/m-$1.36n/m-$1.35n/m-$1.90n/m-$10.78n/m-$3.77n/m-$0.19n/m-$2.62-2481.8%
EPS (Diluted)-$0.78n/m-$1.36n/m-$1.35n/m-$1.90n/m-$10.78n/m-$3.77n/m-$0.19n/m-$2.62-2481.8%
Diluted Shares (Avg)69M+1.0%68M+0.9%68M+1.0%N/A68M+1.0%68M+0.9%68M+0.9%N/A

QDEL Balance Sheet

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QDEL quarterly balance sheet
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-QQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Total Assets$5.8B+1.9%$5.7B-10.4%$5.6B-12.9%$5.8B-10.2%$5.7B-16.6%$6.4B-4.6%$6.5B-3.6%$6.4B-25.0%
Current Assets$1.4B+5.8%$1.4B+7.4%$1.4B+9.4%$1.4B+18.7%$1.4B-3.2%$1.3B-4.5%$1.3B+3.8%$1.2B-7.0%
Cash & Equivalents$166.4M+69.6%$123.4M-18.7%$140.4M+10.5%$169.8M+72.7%$98.1M-31.7%$151.7M+41.8%$127.1M+61.9%$98.3M-17.3%
Short-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0-100.0%
Inventory$642.7M+4.7%$618.9M+6.9%$611.5M+8.6%$577.6M+8.2%$613.8M+6.4%$578.7M-3.9%$563.2M-3.4%$533.7M-7.6%
Accounts Receivable$375.5M-2.8%$352.0M+28.0%$359.9M+25.8%$417.0M+47.7%$386.5M+31.1%$275.0M+2.0%$286.0M+5.3%$282.4M-6.9%
Long-Term Investments$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0n/m$0-100.0%
GoodwillN/AN/AN/A$0-100.0%$0-100.0%$711.1M-2.9%$670.9M-8.7%$649.5M-73.9%
Total Liabilities$4.0B+9.7%$3.9B+9.9%$3.8B+9.0%$3.8B+11.9%$3.6B+0.7%$3.6B+2.0%$3.5B+2.0%$3.4B-3.3%
Current Liabilities$1.1B+39.0%$993.4M-13.0%$962.4M-8.1%$966.1M-3.3%$767.9M-25.3%$1.1B+22.5%$1.0B+34.3%$998.8M+19.8%
Non-Current Liabilities$2.9B+1.8%$2.9B+20.6%$2.8B+16.5%$2.9B+18.1%$2.9B+11.0%$2.4B-5.4%$2.4B-7.6%$2.4B-10.4%
Long-Term Debt$2.5B+0.7%$2.5B+22.4%$2.5B+16.8%$2.5B+15.4%$2.5B+14.7%$2.1B-6.1%$2.1B-6.0%$2.1B-5.9%
Total Equity$1.8B-12.0%$1.8B-36.4%$1.9B-38.2%$1.9B-35.7%$2.0B-36.1%$2.8B-12.0%$3.0B-9.4%$3.0B-40.4%
Retained Earnings-$1.2Bn/m-$1.2Bn/m-$1.1B-983.7%-$996.0M-833.4%-$865.3M-375.4%-$132.3M-139.6%$123.1M-74.4%$135.8M-93.8%

QDEL Cash Flow Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QDEL quarterly cash flow statement
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Operating Cash Flow$19.6Mn/m-$110.6Mn/m-$33.0M-150.3%$131.9M+107.1%-$45.5M-138.6%-$46.8Mn/m$65.6Mn/m$63.7M-20.8%
Depreciation & Amortization$119.6M+6.7%$116.7M+5.8%$112.9M+5.4%$112.5M+2.9%$112.1M-0.9%$110.3M-5.0%$107.1M-6.8%$109.3M-5.3%
Stock-Based Compensation$12.0M+11.1%$12.0M-6.3%$10.7M-7.8%N/A$10.8M-13.6%$12.8M+14.3%$11.6M+28.9%N/A
Capital Expenditures$21.0M-58.0%$25.5M-32.0%$34.0M-39.5%$44.5M-5.7%$50.0M+7.5%$37.5M+6.2%$56.2M-15.0%$47.2M-2.9%
Free Cash Flow-$1.4Mn/m-$136.1Mn/m-$67.0M-812.8%$86.6M+424.8%-$95.5M-233.8%-$84.3Mn/m$9.4Mn/m$16.5M-48.1%
Investing Cash Flow-$20.9Mn/m-$107.3Mn/m-$34.0Mn/m-$49.6Mn/m-$53.9Mn/m-$33.0Mn/m-$56.2Mn/m-$37.9Mn/m
Financing Cash Flow$44.1M-4.1%$200.6M+94.2%$37.6M+113.6%-$11.1Mn/m$46.0Mn/m$103.3M-36.4%$17.6Mn/m-$68.9Mn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

QDEL Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

QDEL quarterly financial ratios
MetricQ3'2610-QQ2'2610-QQ1'2610-QQ4'2510-KQ3'2510-QQ2'2510-QQ1'2510-QQ4'2410-K
Gross Margin46.8%-1.2pp43.3%-1.5pp42.6%-7.0pp44.3%-1.8pp47.9%-0.5pp44.8%+1.4pp49.5%+2.8pp46.1%-5.4pp
Operating Margin-1.2%-3.5%+26.0pp-5.1%-9.8pp-9.2%+5.0pp-100.7%-29.4%-11.0pp4.7%-14.2%-19.6pp
Net Margin-8.7%-14.7%+26.9pp-14.8%-13.0pp-18.1%+7.1pp-104.7%-41.6%-18.4pp-1.8%-25.2%-26.1pp
Return on Equity-3.0%+33.0pp-5.2%+3.9pp-5.0%-4.5pp-6.8%-0.8pp-36.0%-35.4pp-9.2%-4.5pp-0.4%+51.2pp-6.0%-6.1pp
Return on Assets-0.9%+12.0pp-1.6%+2.4pp-1.6%-1.4pp-2.3%+0.5pp-12.9%-12.6pp-4.0%-1.8pp-0.2%+25.3pp-2.8%-2.9pp
Current Ratio1.36-0.4x1.39+0.3x1.43+0.2x1.50+0.3x1.78+0.4x1.12-0.3x1.20-0.4x1.22-0.4x
Debt-to-Equity1.40+0.2x1.43+0.7x1.33+0.6x1.29+0.6x1.23+0.5x0.740.0x0.700.0x0.72+0.3x
Liabilities-to-Equity2.23+0.4x2.22+0.9x2.04+0.9x2.00+0.9x1.79+0.7x1.28+0.2x1.16+0.1x1.15+0.4x
Asset Turnover0.110.0x0.110.0x0.110.0x0.130.0x0.120.0x0.100.0x0.110.0x0.110.0x
FCF Margin-0.2%+13.4pp-21.6%-7.8pp-10.8%-12.2pp12.0%+9.6pp-13.6%-23.5pp-13.7%+7.2pp1.4%+10.8pp2.3%-1.9pp

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it. Market cap is stated at each company's latest close.

Company Fiscal year Revenue Net income Net margin Market cap Health score
QuidelOrtho Corporation QDEL FY2025 $2.7B -$1.1B -41.4% $570.9M 21/100
Cytek Biosciences, Inc. CTKB FY2025 $201.5M -$66.5M -33.0% $800.4M 44/100
Varex Imaging Corporation VREX FY2025 $844.6M -$70.3M -8.3% $768.6M 36/100
Bioventus Inc. BVS FY2025 $568.1M $22.7M 4.0% $676.5M 43/100
InMode Ltd. INMD FY2025 $370.5M $93.8M 25.3% $714.7M 75/100
Delcath Systems Inc DCTH FY2025 $85.2M $2.7M 3.2% $653.7M 52/100

Frequently Asked Questions

QuidelOrtho Corporation (QDEL) reported $2.7B in total revenue for fiscal year 2025. This represents a -1.9% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

QuidelOrtho Corporation (QDEL) revenue declined by 1.9% year-over-year, from $2.8B to $2.7B in fiscal year 2025.

No, QuidelOrtho Corporation (QDEL) reported a net loss of $369.2M over the trailing 12 months to September 27, 2026. In fiscal year 2025 it reported a net loss of $1.1B, with a net profit margin of -41.4%.

QuidelOrtho Corporation (QDEL) reported diluted earnings per share of -$16.69 for fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

QuidelOrtho Corporation (QDEL) had EBITDA of -$477.2M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

As of fiscal year 2025, QuidelOrtho Corporation (QDEL) had $169.8M in cash and equivalents against $2.5B in long-term debt.

QuidelOrtho Corporation (QDEL) had a gross margin of 46.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

QuidelOrtho Corporation (QDEL) had an operating margin of -33.7% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

QuidelOrtho Corporation (QDEL) had a net profit margin of -41.4% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

QuidelOrtho Corporation (QDEL) has a return on equity of -58.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

QuidelOrtho Corporation (QDEL) recorded an outflow of $83.0M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

QuidelOrtho Corporation (QDEL) generated $105.2M in operating cash flow during fiscal year 2025, representing cash generated from core business activities.

QuidelOrtho Corporation (QDEL) had $5.8B in total assets as of fiscal year 2025, including both current and long-term assets.

QuidelOrtho Corporation (QDEL) invested $188.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

QuidelOrtho Corporation (QDEL) invested $186.2M in research and development during fiscal year 2025.

QuidelOrtho Corporation (QDEL) had 68M shares outstanding as of fiscal year 2025.

QuidelOrtho Corporation (QDEL) had a current ratio of 1.50 as of fiscal year 2025, which is considered adequate.

QuidelOrtho Corporation (QDEL) had a debt-to-equity ratio of 1.29 as of fiscal year 2025. We compute it as long-term debt divided by total shareholder equity, where long-term debt is the noncurrent part of the company's borrowings, so debt due within the next twelve months is not counted.

QuidelOrtho Corporation (QDEL) had a liabilities-to-equity ratio of 2.00 as of fiscal year 2025, which is total liabilities divided by total shareholder equity. Total liabilities counts every obligation on the balance sheet (payables, deposits, insurance reserves and deferred taxes as well as borrowings), so this ratio usually runs well above debt-to-equity.

QuidelOrtho Corporation (QDEL) had a return on assets of -19.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

QuidelOrtho Corporation (QDEL) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to September 27, 2026). The market capitalization is $570.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

QuidelOrtho Corporation (QDEL) trades at 0.2x sales, its market capitalization divided by $2.6B revenue, trailing 12 months to September 27, 2026. The market capitalization is $570.9M as of Nov 20, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

QuidelOrtho Corporation (QDEL) has an Altman Z-Score of -0.11, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

QuidelOrtho Corporation (QDEL) has a Piotroski F-Score of 6 out of 9, indicating neutral financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

QuidelOrtho Corporation (QDEL) reported a net loss of $1.1B while generating $105.2M in operating cash flow. Operations generated cash despite the loss, but with no positive earnings behind it, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

QuidelOrtho Corporation (QDEL) reported an operating loss of $919.2M against $177.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

QuidelOrtho Corporation (QDEL) scores 21 out of 100 on our Financial Health Score, indicating weak standing within its operating companies peer group. The score is the average of six dimensions (Profitability, Growth, Leverage, Liquidity, Cash Flow, Returns), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.

Back to top